Stocks and Investing
Stocks and Investing
Thu, April 29, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Michael Schmitz Maintained (BPMC) at Strong Buy with Decreased Target to $110 on, Apr 29th, 2021
Michael Schmitz of Guggenheim, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Decreased Target from $125 to $110 on, Apr 29th, 2021.
Michael has made no other calls on BPMC in the last 4 months.
There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 3 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brad Canino of "Credit Suisse" Initiated at Hold and Held Target at $100 on, Wednesday, March 31st, 2021
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $105 on, Thursday, February 18th, 2021
- Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $95 on, Thursday, February 18th, 2021
These are the ratings of the 2 analyists that currently disagree with Michael
- Liana Moussatos of "Wedbush" Maintained at Buy with Increased Target to $136 on, Tuesday, April 13th, 2021
- Andrew Berens of "SVB Leerink" Maintained at Buy with Increased Target to $127 on, Tuesday, January 12th, 2021
Contributing Sources